| |
Present study (<35yrs ) |
Mohanti et al. [8](<35yrs) |
Raina et al.[9](≤35yrs) |
M. Colleoni et al. [21](<35yrs) |
RA Walker et al. (< 35 yrs)[16] |
Hanna Fredholm et al. (<35yrs)[22] |
| % of patients |
11.25% |
5.5% |
8% |
13% |
- |
2.1% |
| Stage
I
II
III
IV |
0%
33.3%
52.8%
13.9% |
3%
20%
55%
22% |
3%
20%
55%
22% |
48% |
-
-
-
- |
26%
54%
11%
3.2% |
| HPE |
IDC 100% |
IDC 94% |
IDC93% |
- |
IDC 100% |
|
| Er /pr +
Her 2 +
Triple negative |
38.9%
22.2%
50% |
40%
37%
31% |
33
30
33 |
Er neg38%, prneg 49%
39%
Na |
Er + 57%,pr+37%
22% |
Er/pr + 46 |
| Grade
I
II
III
Ki 67 |
0%
13.9%
86.1%
- |
60% high grade |
30% |
8.2%
29.9%
61.9%
KI 67 ≥ 20% =71% |
0%
30%
70%
low 20%.medium 13% ,high 67% |
3%
8%
24% |
| Pathological node + |
51 % |
56% |
55% |
33 %(1-3 node)
10% > 10 node + |
46% |
43% (1-3node 25.1% ≥ nodes18.5%) |
| LVE |
43% |
- |
- |
48% |
|
|
